Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073728064> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2073728064 endingPage "S150" @default.
- W2073728064 startingPage "S150" @default.
- W2073728064 abstract "Purpose/Objective(s): To define the optimal dose for I-125 prostate implants by correlating post implant CT dosimetry findings with biochemical failure and toxicity. Materials/Methods: Patients with low to intermediate-risk prostate cancer treated with I-125 brachytherapy were analyzed. Between 2003 and 2009, a total of 682 patients were observed from 24 to 100 months (median: 56 months). According to National Comprehensive Cancer Network risk classification, 457 patients with low-risk, 224 patients with intermediaterisk and one patient with high-risk were included. Implant dose was defined as the D90-P (dose delivered to 90% of the prostate from on the 1month postimplant CT-based dose-volume histogram). The D90s ranged from 126 to 233 Gy (median: 185 Gy). Patients were analyzed by dose categories: <140 Gy (n Z 9), 140 to <160 Gy (n Z 75), 160 to <180 Gy (n Z 196), 180 to <200 Gy (n Z 277), and S 200 Gy (n Z 125). The effect of dose on biochemical control using the ASTRO definition was tested with actuarial methods. Genitourinary (GU) and gastrointestinal (GI) toxicity was prospectively assessed using the Common Terminology Criteria for Adverse Events ver.4.0. The effect of dose on GU and GI toxicity S grade 2 was tested with actuarial methods. Results: Freedom from biochemical failure (FFBF) at 5 years was 95% for all patients. FFBF at 5 years was 67% for D90-P doses <140 Gy, 92% for 140 to <160 Gy, 95% for 160 to <180 Gy, 98% for 180 to < 200 Gy, and 99% for S200Gy (p < 0.001). The most significant cut point was seen at a level of 160 Gy (p Z 0.003), secondly at a level of 180 Gy (p Z 0.006). A multivariate analysis using dose, PSA, Gleason score, T-stage, risk groups, neoadjuvant hormone, prostate volume, technique, and prescription found dose to be the most significant factor affecting FFBF. The incidences of late GU toxicities of S grade 2 at 5 years were 3% for the D90-P doses <160 Gy, 7% for 160 to <180 Gy, and 10% for S180 Gy (p Z 0.054). Five-year rates of any grade 3 GU toxicities were 0%, 2%, and 1%, respectively (p Z 0.145). Rates of late GI toxicities of S grade 2 at 5 years were 0%, 1%, and 3%, respectively (p Z 0.143). Conclusions: Improvements in FFBF rates were seen with increasing D90P levels. Adequate I-125 implants should deliver a D90-P of 160 Gy or higher on the basis of postimplant dosimetry on day 30. Greater D90-P doses are associated with a small increase in late GU toxicity S grade 2, and no increase in grade 3 GU toxicity or any late GI toxicity. This shows the feasibility, safety and better treatment results of high D90s, even with greater than 180 Gy. Author Disclosure: A. Yorozu: None. S. Saito: None. K. Toya: None. K. Yoshida: None." @default.
- W2073728064 created "2016-06-24" @default.
- W2073728064 creator A5008082162 @default.
- W2073728064 creator A5048167363 @default.
- W2073728064 creator A5049234946 @default.
- W2073728064 creator A5059493098 @default.
- W2073728064 date "2012-11-01" @default.
- W2073728064 modified "2023-10-16" @default.
- W2073728064 title "A Dose-response Analysis of Biochemical Control and Toxicity for I-125 Prostate Brachytherapy" @default.
- W2073728064 doi "https://doi.org/10.1016/j.ijrobp.2012.07.386" @default.
- W2073728064 hasPublicationYear "2012" @default.
- W2073728064 type Work @default.
- W2073728064 sameAs 2073728064 @default.
- W2073728064 citedByCount "0" @default.
- W2073728064 crossrefType "journal-article" @default.
- W2073728064 hasAuthorship W2073728064A5008082162 @default.
- W2073728064 hasAuthorship W2073728064A5048167363 @default.
- W2073728064 hasAuthorship W2073728064A5049234946 @default.
- W2073728064 hasAuthorship W2073728064A5059493098 @default.
- W2073728064 hasBestOaLocation W20737280641 @default.
- W2073728064 hasConcept C121608353 @default.
- W2073728064 hasConcept C126322002 @default.
- W2073728064 hasConcept C143998085 @default.
- W2073728064 hasConcept C19527891 @default.
- W2073728064 hasConcept C2776235491 @default.
- W2073728064 hasConcept C2777416452 @default.
- W2073728064 hasConcept C29730261 @default.
- W2073728064 hasConcept C2989005 @default.
- W2073728064 hasConcept C509974204 @default.
- W2073728064 hasConcept C71924100 @default.
- W2073728064 hasConceptScore W2073728064C121608353 @default.
- W2073728064 hasConceptScore W2073728064C126322002 @default.
- W2073728064 hasConceptScore W2073728064C143998085 @default.
- W2073728064 hasConceptScore W2073728064C19527891 @default.
- W2073728064 hasConceptScore W2073728064C2776235491 @default.
- W2073728064 hasConceptScore W2073728064C2777416452 @default.
- W2073728064 hasConceptScore W2073728064C29730261 @default.
- W2073728064 hasConceptScore W2073728064C2989005 @default.
- W2073728064 hasConceptScore W2073728064C509974204 @default.
- W2073728064 hasConceptScore W2073728064C71924100 @default.
- W2073728064 hasIssue "3" @default.
- W2073728064 hasLocation W20737280641 @default.
- W2073728064 hasOpenAccess W2073728064 @default.
- W2073728064 hasPrimaryLocation W20737280641 @default.
- W2073728064 hasRelatedWork W1553031414 @default.
- W2073728064 hasRelatedWork W1994180560 @default.
- W2073728064 hasRelatedWork W2023503398 @default.
- W2073728064 hasRelatedWork W2039692113 @default.
- W2073728064 hasRelatedWork W2064777290 @default.
- W2073728064 hasRelatedWork W2065840363 @default.
- W2073728064 hasRelatedWork W2089236883 @default.
- W2073728064 hasRelatedWork W2094494178 @default.
- W2073728064 hasRelatedWork W2105375423 @default.
- W2073728064 hasRelatedWork W2475208052 @default.
- W2073728064 hasVolume "84" @default.
- W2073728064 isParatext "false" @default.
- W2073728064 isRetracted "false" @default.
- W2073728064 magId "2073728064" @default.
- W2073728064 workType "article" @default.